Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiang, Flüchter, Patricia, Nickel, Katharina, Meckel, Katharina, Messerschmidt, Janin, Böckle, David, Knorz, Sebastian, Steinhardt, Maximilian Johannes, Krummenast, Franziska, Danhof, Sophia, Einsele, Hermann, Kortüm, K. Martin, Rasche, Leo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225914/
https://www.ncbi.nlm.nih.gov/pubmed/32340174
http://dx.doi.org/10.3390/cancers12041035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225914/
https://www.ncbi.nlm.nih.gov/pubmed/32340174
http://dx.doi.org/10.3390/cancers12041035

Ejemplares similares